放化疗后中药维持治疗广泛期小细胞肺癌的临床研究  

Clinical research of extensive stage small cell lung cancer treated by Chinese medicine after chemoradiotherapy

作　　者：冉文华[1] 黄朝森[2] 王恩元[3] 任必勇[1] 黄小平[1] 莫运波[4] 张军[1] 

机构地区：[1]重庆三峡中心医院肿瘤科,万州404000 [2]重庆三峡中心医院超声科,万州404000 [3]重庆三峡中心医院中医科,万州404000 [4]重庆三峡中心医院儿童分院,万州404000

出　　处：《重庆医科大学学报》2011年第3期356-358,共3页Journal of Chongqing Medical University

基　　金：重庆市卫生局科研项目资助(编号:2009-2-056)

摘　　要：目的:探讨常规化放疗后用中药维持治疗广泛期小细胞肺癌能否提高生存率。方法:88例未经手术治疗的广泛期小细胞肺癌病例随机分为化放疗组(对照组)和化放疗后+中药维持治疗组(研究组),每组分别为44例。对照组与研究组的化放疗方案均相同,研究组于化放疗治疗结束后加服中药喜丹汤治疗。结果:对照组与研究组中位生存期分别为7.6个月、11.1个月,两组1年生存率为18.2%和38.6%(χ2=4.53,P<0.05),2年生存率为4.5%和18.1%(χ2=4.06,P<0.05),3年生存率为2.3%和13.6%(χ2=3.88,P<0.05),5年生存率为2.3%和6.8%(χ2=1.05,P>0.05)。结论:常规化放疗后加用中药维持治疗能提高广泛期小细胞肺癌患者的生存率,延长其生存期。Objective： To observe whether Chinese traditional medicine improves survival rate of extensive stage small cell lung cancer（ES-SCLC） patients after conventional chemoradiotherapy.Methods： Eighty-eight patients with ES-SCLC treated without surgery were divided randomly into the control group（chemoradiotherapy） and the experimental group（chemoradiotherapy plus traditional Chinese medicine treatment）,with forty-four patients in each group.The treatment in the two groups was the same except that XIDAN soup was given in the experimental group after chemoradiotherapy.Results： The median survivals for the control group and experimental group were 7.6 months and 11.1 months respectively.The overall 1 year survival rates of ES SCLC patients in the two groups were 18.2% and 38.6%（χ2=4.53,P0.05）;2-year survival rates were 4.5% and 18.1%（χ2=4.06,P0.05）;3-year survival rates were 2.3% and 13.6%（χ2= 3.88,P0.05）,and 5-year survival rates were 2.3% and 6.8%（χ2=1.05,P0.05）respectively.Conclusion： Chinese medicine treatment after conventional chemoradiotherapy can improve the survival rate and prolong the life time of ES-SCLC patients.

关 键 词：广泛期小细胞肺癌 放化疗后 中药后续治疗 中西医结合治疗 

分 类 号：R734.2[医药卫生—肿瘤]